IP Library Granted Patent US 10,428,025
Granted Patent B2
US 10,428,025 · App. 16/280,534 · Granted Oct 1, 2019

Antifungal compound process

Inventors: William J. Hoekstra (Durham, NC); Christopher M. Yates (Raleigh, NC); Mark Behnke (Poolesville, MD); Asaf Alimardanov (North Bethesda, MD); Scott A. David (Huntsburg, OH); Douglas Franklin Fry (Euclid, OH)
Assignees: Mycovia Pharmaceuticals, Inc.; The United States of America, as represented by the Secretary, Department of Health and Human Services
C07D213/50C07D213/30C07D213/38C07D401/06C07D405/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,428,025
App. No.
16/280,534
Granted
Oct 1, 2019
Kind
B2
Abstract

The present invention relates to a process for preparing compound 1 that is useful as an antifungal agent. In particular, the invention seeks to provide new methodology for preparing compound 1 and substituted derivatives thereof.

Claims (32)

1. A compound of formula VI* or VIa*, or a mixture thereof:

wherein each R 1 is independently halo or

each Y 1 is independently —OH, —OSO 2 -alkyl, —OSO 2 -substituted alkyl, —OSO 2 -aryl, —OSO 2 -substituted aryl, —O(C═O)-alkyl, —O(C═O)-substituted alkyl, —O(C═O)-aryl, —O(C═O)— substituted aryl, or halogen; and

each R 12 is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted hetrocyclyl.

2. The compound of claim 1 , wherein the compound has the formula:

wherein

Y is independently —OH, mesylate, or tosylate; and

each R 1 is independently, halo or

3. A process to prepare compound of formula VI* or VIa*, or a mixture thereof:

comprising

(i) reacting ester 6,

with morpholine to provide morpholine amide 7:

(ii) reacting morpholine amide 7:

with

to provide ketone 3,

(iii) performing olefination of ketone 3,

to provide olefin 2-5,

(iv) reacting olefin 2-5,

under asymmetric dihydroxylation conditions to provide a compound of formula 2-6b or 2-6d,

or a mixture thereof;

(v) activating the primary alcohol of 2-6b or 2-6d to provide VI* or VIa*

or a mixture thereof;

wherein M is Mg or MgX; and X is halogen;

the asymmetric dihydroxylation conditions comprise:

(i) AD-mix alpha or AD-mix beta; or

(ii) a first oxidant in catalytic amount selected from OsO 4 or K 2 OsO 2 (OH) 4 ;

(iii) a second oxidant in stoichiometric amount selected from K 3 Fe(CN) 6 or N-methylmorpholine-N-oxide;

(iv) a base selected from NaHCO 3 , Na 2 CO 3 , Cs 2 CO 3 , or K 2 CO 3 ; and

(v) a chiral ligand that is selected from (DHQ) 2 PHAL, (DHQD) 2 PHAL, (DHQD) 2 AQN, (DHQ) 2 AQN, (DHQD) 2 PYR, and (DHQ) 2 PYR; and

each R 1 is independently, halo or

each Y 1 is independently —OH, —OSO 2 -alkyl, —OSO 2 -substituted alkyl, —OSO 2 -aryl, —OSO 2 -substituted aryl, —O(C═O)-alkyl, —O(C═O)-substituted alkyl, —O(C═O)-aryl, —O(C═O)— substituted aryl, or halogen; and

each R 12 is independently H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl, or optionally substituted hetrocyclyl.

Continuity (3)
Division 15126392
Provisional Application 61955599 · Mar 19, 2014
Related Publication 20190185430A1 · Jun 20, 2019